All Smoflipid® Clinical Information


Liver Function

Levels of AST/ALT in patients receiving Smoflipid® were significantly lower versus soybean oil emulsions7,18

liver functions

STUDY TAKEAWAY
Smoflipid® showed lower concentrations of liver enzymes (ALT, AST) compared to soybean oil lipid emulsions, indicating an improvement in the patient's liver function.7

Monitor liver function. If Smoflipid® treated patients develop liver enzyme abnormalities, consider discontinuation or dose reduction.


Triglyceride Data

Studies showed triglyceride levels increased less with Smoflipid® compared to lipid emulsions with higher soybean oil content.8,18

triglyceride data

STUDY TAKEAWAY
In postoperative surgical patients, Smoflipid® demonstrated a lower triglyceride increase compared to those patients who received a lipid emulsion with a higher soybean oil content.18

Monitor serum triglycerides before and during treatment with Smoflipid®. Company-sponsored studies showed that mean triglyceride levels from baseline values to week 4 were similar in both the Smoflipid® and comparator groups.11


Fatty Acid Profile

Smoflipid® has a 2.5:1 ω-6:ω-3 fatty acid ratio11

triglyceride data
  • The ω-6:ω-3 fatty acid ratio in Smoflipid® has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
  • The fatty acid ratio in Smoflipid® is in line with expert recommendations.12-15
  • Smoflipid® has a lower amount of ω-6 fatty acids compared to 100% soybean oil emulsion11, 16, 17

  • Smoflipid® meets the essential fatty acid requirements of adults11


Fatty Acid Composition of Current IVLEs

current IVLEs

a Data on file. Fresenius Kabi. 2016.

The ω-6:ω-3 fatty acid ratio in Smoflipid® has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.



EPA/DHA

  • Smoflipid® has been shown to improve EPA and DHA levels in adult patients7,23
    – ESPEN states, "Addition of EPA and DHA to lipid emulsions has demonstrable effects on cell membranes and inflammatory processes." (Grade B)21

α-tocopherol

  • An additive in Smoflipid® that prevents the oxidation of lipids in the formulation (~200 mg/L)7,18,23
    – In clinical studies, Smoflipid® has been shown to increase plasma α-tocopherol levels7,18,23

References

  1. Klek S, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid): a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231.
  1. Wu MH, et al. Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery. JPEN J Parenter Enteral Nutr. 2014;38(7):800-808.
  1. Smoflipid [prescribing information].
  2. Grimble RH. Fatty acid profile of modern lipid emulsions: scientific consideration for creating the ideal composition. Clin Nutr Suppl. 2005;1(3):9-15.
  3. Waitzberg DL, et al. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr. 2006;30(4):351-367.
  4. Mayer K, et al. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care. 2006;9(2):140-148.
  5. Grimm H, et al. Immunonutrition-supplementary amino acids and fatty acids ameliorate immune deficiency in critically ill patients. Arch Surg. 2001;386(5):369-376.
  6. Intralipid [prescribing information].
  7. Nutrilipid [prescribing information].
  1. Antébi H, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr. 2004;28(3):142-148.
  1. Singer P, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr. 2009;28(4):387-400.
  1. Grimm H, et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006;45(1):55-60.